Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein

Molecular Pharmacology

Volumn 67, Issue 2, 2005, Pages 356-364

  Seung, Joon Baek ^a,b   Kim, Jong Sik ^a   Moore, Scott M ^a   Lee, Seong Ho ^b   Martinez, Jeanelle ^a   Eling, Thomas E ^a,c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Lab of Molecular Carcinogenesis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; DICLOFENAC; EARLY GROWTH RESPONSE FACTOR 1; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1 PROTEIN; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN; SALICYLATE SODIUM; SULINDAC SULFIDE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMEDIATE-EARLY PROTEINS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; UP-REGULATION; ZINC FINGERS;

EID: 13444282673     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.005108     Document Type: Article

References (48)

1. Baek SJ, Horowitz JM, and Eling TE (2001a) Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 276:33384-33392.
2. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, and Eling TE (2004) Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 279:6883-6892.
3. Baek SJ, Kim KS, Nixon JB, Wilson LC, and Eling TE (2001b) Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-908.
4. Baek SJ, Wilson LC, and Eling TE (2002a) Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23:425-434.
5. Baek SJ, Wilson LC, Hsi LC, and Eling TE (2003) Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278:5845-5853.
6. Baek SJ, Wilson LC, Lee CH, and Eling TE (2002b) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301:1126-1131.
7. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, et al. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 94:11514-11519.
8. Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, and Suter-Crazzolara C (1999) Characterization of the rat, mouse and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 237:105-111.
9. Bottone FG Jr, Baek SJ, Nixon JB, and Eling TE (2002) Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 132:773-778.
10. Bottone FG Jr, Martinez JM, Collins JB, Afshari CA, and Eling TE (2003) Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J Biol Chem 278:25790-25801.
11. Davis W Jr, Chen ZJ, Ile KE, and Tew KD (2003) Reciprocal regulation of expression of the human adenosine 5′-triphosphate binding cassette, sub-family A, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Res 31:1097-1107.
12. Decker EL, Skerka C, and Zipfel PF (1998) The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J Biol Chem 273:26923-26930.
13. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, and Khachigian LM (2003) Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9:1026-1032.
14. Ferrandez A, Prescott S, and Burt RW (2003) COX-2 and colorectal cancer. Curr Pharm Des 9:2229-2251.
15. Grosch S, Tegeder I, Schilling K, Maier TJ, Niederberger E, and Geisslinger G (2003) Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J 17:1316-1318.
16. Hromas R, Hufford M, Sutton J, Xu D, Li Y, and Lu L (1997) PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354:40-44.
17. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, and Adamson ED (1997) Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72:102-109.
18. Huang RP, Liu C, Fan Y, Mercola D, and Adamson ED (1995) Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 55:5054-5062.
19. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, and Nakamura Y (2002) Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 292:498-512.
20. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
21. Khachigian LM, Williams AJ, and Collins T (1995) Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 270:27679-27686.
22. Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, and Eling TE (2002) Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 122:1388-1398.
23. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, and Klamut HJ (2000) Placental TGF-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275:20127-20135.
24. Liu C, Rangnekar VM, Adamson E, and Mercola D (1998) Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 5:3-28.
25. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankurst S, Russell PJ, and Breit SN (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034-5040.
26. McEntee MF, Chiu CH, and Whelan J (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20:635-640.
27. Monks A, Harris E, Hose C, Connelly J, and Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766-772.
28. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, and Rangnekar VM (1997) Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 272:20131-20138.
29. Newman D, Sakaue M, Koo JS, Kim KS, Baek SJ, Eling T, and Jetten AM (2003) Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 63:557-564.
30. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA and Thompson DD (1998) Cloning and characterization of a novel member of the transforming growth factor-b/bone morphogenetic protein family. J Biol Chem 273:13760-13767.
31. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909-2915.
32. Raychowdhury R, Schafer G, Fleming J, Rosewicz S, Wiedenmann B, Wang TC, and Hocker M (2002) Interaction of early growth response protein 1 (Egr-1), specificity protein 1 (Sp1) and cyclic adenosine 3′5′-monophosphate response element binding protein (CREB) at a proximal response element is critical for gastrin-dependent activation of the chromogranin A promoter. Mol Endocrinol 16:2802-2818.
33. Reddy BS and Rao CV (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 21:155-164.
34. Ricchi P, Zarrilli R, Di Palma A, and Acquaviva AM (2003) Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88:803-807.
35. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, and Ahnen DJ (2003) Sulindac metabolites induce caspase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Ther 2:885-892.
36. Robles AI, Bemmels NA, Foraker AB, and Harris CC (2001) APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61:6660-6664.
37. Srivastava S, Weitzmann MN, Kimble RB, Rizzo M, Zahner M, Milbrandt J, Ross FP, and Pacifici R (1998) Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Investig 102:1850-1859.
38. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529-1536.
39. Tan M, Wang Y, Guan K, and Sun Y (2000) PTGF-β, a type beta transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci USA 97:109-114.
40. Thun MJ (1996) NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 25:333-348.
41. Thun MJ and Heath CW Jr (1995) Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies. Prev Med 24:116-118.
42. Thun MJ, Henley SJ, and Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 94:252-266.
43. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, et al. (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401.
44. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, and DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 94(2):following 271, 1998]. Cell 93:705-716.
45. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, and de Belle I (2001) The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3:1124-1128.
46. Wechter WJ, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, and McCracken JD (1997) R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 57:4316-4324.
47. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, and Greenberg NM (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60:2203-2208.
48. Wilson LC, Baek SJ, Call A, and Eling TE (2003) Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 105:747-753.